Suivez nous sur les réseaux sociaux
Cet outil a vocation à informer, diffuser l’information auprès des jeunes cardiologues (internes, assistants, chefs de cliniques, jeunes praticiens, etc.), et faciliter les échanges.
Voici un aperçu rapide des sujets abordés dans cette publication :
Toutes nos publications
Dernières publications
Une question ?
Publications
In-hospital and 1-year Incremental Prognostic Value of Drug Abuse Detection in Acute Heart Failure
Voici un aperçu rapide des sujets abordés dans cette publication :
In-hospital and 1-year Incremental Prognostic Value of Drug Abuse Detection in Acute Heart Failure
Michele Senni, Antonello Gavazzi, Fabrizio Oliva, Andrea Mortara, Renato Urso, Massimo Pozzoli, Marco Metra, Donata Lucci, Lucio Gonzini, Vincenzo Cirrincione, Laura Montagna, Andrea Di Lenarda, Aldo P Maggioni, Luigi Tavazzi, for the IN HF Outcome Investigators
International Journal of Cardiology, Volume 173, Issue 2, 1 May 2014, Pages 163-169
PMID: 24630337
DOI: 10.1016/j.ijcard.2014.02.018
Abstract
Background
To investigate the outcomes of hospitalized patients with both de-novo and worsening heart failure (HF) with preserved left ventricular ejection fraction (LVEF) (HFpEF) (LVEF ≥ 50%), compared to those with reduced LVEF (HFrEF).
Methods and Results
We studied 1669 patients (22.6% HFpEF) hospitalized for acute HF in the prospective multi-center nationwide Italian Network on Heart Failure (IN-HF) Outcome Registry. In all patients LVEF was assessed during hospitalization. De-novo HF presentations constituted 49.6% of HFpEF and 43.1% of HFrEF hospitalizations. All-cause mortality during hospitalization was lower in HFpEF than HFrEF (2.9% vs 6.5%, p=0.01), but this mortality difference was not significant at 1 year (19.6% vs 24.4%, p=0.06), even after adjusting for clinical covariates. Similarly, there were no differences in 1-year mortality between HFpEF and HFrEF when compared by cause of death (cardiovascular vs non-cardiovascular) or mode of presentation (worsening HF vs de novo). Rehospitalization rates (all-cause, non-cardiovascular, cardiovascular, HF-related) at 90 days and 1 year were also similar. Mode of presentation influenced rehospitalizations in HFpEF, where those presenting with worsening HFpEF had higher all-cause (36.8% vs 21.6%, p=0.001), cardiovascular (28.1% vs 14.9%, p=0.002), and HF-related (21.1% vs 7.7%, p=0.0003) rehospitalization rates at 1 year compared to those with de novo presentations.
Conclusions
Outcomes at 1 year following hospitalization for HFpEF are as poor as that of HFrEF. A prior history of HF decompensation or hospitalization identifies patients with HFpEF at particularly high risk of recurrent events. These findings may have implications for clinical practice, quality and process improvements and trial design.